AI assistant
Gvs — Earnings Release 2025
Aug 7, 2025
4164_rns_2025-08-07_6c0ad5fe-3f9d-48e9-b468-ee73b3447bc9.pdf
Earnings Release
Open in viewerOpens in your device viewer

| Informazione Regolamentata n. 2251-52-2025 |
Data/Ora Inizio Diffusione 7 Agosto 2025 14:14:48 |
Euronext Milan | ||
|---|---|---|---|---|
| Societa' | : | GVS | ||
| Identificativo Informazione Regolamentata |
: | 209066 | ||
| Utenza - referente | : | GVSN03 - Bala Rozemaria | ||
| Tipologia | : | 1.2 | ||
| Data/Ora Ricezione | : | 7 Agosto 2025 14:14:48 | ||
| Data/Ora Inizio Diffusione | : | 7 Agosto 2025 14:14:48 | ||
| Oggetto | : | GVS: First Half 2025 Consolidated Results Approval |
||
| Testo del comunicato |
Vedi allegato


GVS CONFIRMS ITS LEADERSHIP IN PROFITABILITY, POSTING THE STRONGEST QUARTERLY PERFORMANCE SINCE Q4 2021
GVS H1 2025 Results Highlights
Consolidated revenues up 1.7% at constant exchange rates to 215.6 million euro
Healthcare & Life Sciences division revenues up +2.2% at constant exchange rates compared to H1 2024
Safety division revenues up 8.6% year-on-year at constant exchange rates in the first six months, accelerating versus Q1 2025 performance
Adjusted EBITDA up 4.1% to 54.2 million euro, with a margin for the first half at 25.1%, up 90 basis points year-on-year
Adjusted EBITDA margin for Q2 2025 at 26.2%, +120 basis points vs. Q2 2024, marking the highest profitability since Q4 2021
Adjusted net profit, excluding foreign exchange gains and losses, up 16.2% yearon-year to 26.2 million euro, improving the margin from 10.5% of H1 2024 to 12.1%
Net financial debt at 268.0 million euro, with a post-M&A leverage ratio of 2.4x
***






Zola Predosa (BO), 7 August 2025 – The Board of Directors of GVS S.p.A. (the "Company" or the "Group"), a leading provider of advanced filtration solutions for highly critical applications, met today in Zola Predosa (BO) and approved the consolidated half year report at 30 June 2025, which have been prepared in accordance with IFRS international accounting standards.
ANALYSIS OF THE GROUP'S ECONOMIC PERFORMANCE
In the first half of 2025, GVS reported consolidated revenues of 215.6 million euro, up 1.7% year-onyear at constant exchange rates and 0.4% at current exchange rates.
The Healthcare & Life Sciences division, accounting for 67.8% of total revenues, recorded sales of 146.2 million euro, representing an increase of 2.2% at constant exchange rates (+1.0% at current exchange rates) compared to the first six months of 2024, mainly driven by the acquisition of Haemonetics' whole blood business.
The Safety division, representing 18.7% of total revenues, reached 40.3 million euro, up 8.6% at constant exchange rates (+7.0% at current exchange rates) compared to the same period of the previous year, showing an acceleration versus the growth recorded in the first quarter.
The Mobility division, accounting for 13.5% of total revenues, posted sales of 29.2 million euro, down 8.5% at constant exchange rates (-10.3% at current exchange rates) compared to the same period in 2024. The division's performance was impacted by a slowdown in the automotive sector.
Adjusted EBITDA increased by 4.1% compared to the first six months of 2024 to 54,2 million euro, with a revenue margin of 25.1%, a significant improvement over the 24.2% margin recorded in the same period of the previous year. In the second quarter of 2025, the adjusted EBITDA margin reached 26.2%, up 120 basis points compared to the same quarter of 2024, marking the highest quarterly profitability level since Q4 2021.
Adjusted EBIT amounted to 39.5 million euro, up 4.9% from 37.7 million euro in the same period of the previous year, with a margin on revenues of 18.3%, in line with the growth achieved at the adjusted EBITDA level.
Adjusted net financial expenses - net of FX losses of 22.2 million euro in H1 2025 and FX gains of 3.0 million euro in H1 2024 - decreased in the reporting period, from 7.7 million euro as of June 30, 2024, to 5.0 million euro as of June 30, 2025. This improvement was mainly due to the reduction in the nominal value of outstanding loans in accordance with their respective amortization schedules and to the contractually agreed interest rates.
Adjusted net income, excluding foreign exchange gains/losses and the related tax effects, amounted to 26.2 million euro, up 16.2% compared to the first half of the previous year.
Net financial debt as of June 30, 2025, stood at 268.0 million euro. The 48.2 million euro increase versus December 31, 2024, was primarily attributable to the acquisition of Haemonetics' whole blood business. As part of this transaction, the Group paid 40.5 million euro at closing and recognized an earn-out liability of 8.9 million euro, payable in several annual instalments by February 2028. Excluding the above-mentioned acquisition and extraordinary investments carried out during the period







amounting to 5.6 million euro, net financial debt as of June 30, 2025 decreased by 6.8 million euro compared to December 31, 2024.
BUSINESS OUTLOOK
During the first quarter of 2025, the GVS Group continued on its path of continuous improvement in economic and financial performance, focusing its strategy on:
- the full integration, within the new Transfusion Medicine subdivision, of the whole blood business acquired from Haemonetics at the beginning of the year;
- the continuation of industrial efficiency actions, aimed at supporting a further improvement of the Group's margins;
- the implementation of the new organisational structure of the Healthcare & Life Sciences division, aimed at maximising the growth potential of the different markets.
With regard to the impact of the new tariffs recently introduced by the U.S. administration, the Company notes the following:
- The impact of the new tariffs in the first half of 2025 amounted to approximately Euro 350 thousand;
- The impact in the second half of 2025 is expected to be almost entirely offset by price increases already implemented.
Following the results achieved in the first six months of the year, the Company has updated its fullyear 2025 guidance as follows:
- Mid-to-high single-digit growth in consolidated turnover at constant exchange rates compared to FY2024, in acceleration in the second half of the year thanks to the rampup of Whole Blood revenues;
- an increase in the adjusted EBITDA margin of between 150 and 250 basis points compared to 2024, including the tariff impact;
- a leverage ratio expected to be around 2.2x as of 31 December 2025, including the impact of the ongoing €20m Buyback
STATEMENT PURSUANT TO ARTICLE 154-BIS, SECOND PARAGRAPH OF THE CONSOLIDATED LAW ON FINANCIAL INTERMEDIATION (TUF)
***
The Manager responsible for preparing the company's financial reports, Emanuele Stanco, declares, pursuant to article 154-bis, second paragraph of Legislative Decree 58/98, that the accounting information contained in this press release corresponds to the results in the Company's documents, books and accounting records.


***



The consolidated half year report at 30 June 2025, approved by the Board of Directors today, will be made available to the public at the Company's registered office and can be consulted on the Company's website at www.gvs.com and on the authorised storage mechanism "eMarket Storage", managed by Teleborsa Srl.
***
CONFERENCE CALL
Financial results for H1 2025 will be presented on 7 August 2025 at 16.00 pm CET during a webinar/conference call held by the Group's Senior Management.
The event can be followed in webinar or telephone mode by registering at the link below:
CLICK HERE TO REGISTER FOR THE CONFERENCE CALL & WEBINAR
The presentation given by the Senior Management will be available before the beginning of the conference call on the authorised storage mechanism eMarket Storage, managed by Teleborsa Srl, as well as on the Company's website www.gvs.com (in the section Investor Relations/Financial Presentations).
***
This press release is available on the regulated information dissemination system eMarket SDIR, managed by Teleborsa Srl, as well as on the Company's website www.gvs.com (in the Investor/Press releases section).
***
Contacts
Investor Relations GVS S.p.A. Guido Bacchelli Head of Strategy, Corporate Development and IR [email protected]
DISCLAIMER
This press release contains forward-looking statements concerning future events and operating, economic and financial results of GVS. These forecasts have by their very nature a component of risk and uncertainty, as they depend on the occurrence of future events and developments. Actual results may deviate even significantly from those announced in relation to a multitude of external factors not necessarily under GVS's control.






Consolidated Financial Statements as at 30 June 2025
Consolidated Income Statement
| (In thousands of Euro) | Period of 6 months ended 30 June |
||
|---|---|---|---|
| 2025 | 2024 | ||
| Revenue from contracts with customers | 215,595 | 214,822 | |
| Other revenue and income | 3,684 | 3,901 | |
| Total revenue | 219,279 | 218,723 | |
| Purchases and consumption of raw materials, semi-finished and finished products |
(64,568) | (64,435) | |
| Personnel costs | (68,777) | (69,808) | |
| Services Cost | (31,280) | (29,692) | |
| Other operating costs | (3,076) | (3,721) | |
| EBITDA | 51,578 | 51,067 | |
| Net write downs of financial assets | (281) | (520) | |
| Amortisation, depreciation and write downs | (22,336) | (21,874) | |
| EBIT | 28,961 | 28,673 | |
| Financial income | 758 | 5,026 | |
| Financial costs | (28,349) | (12,508) | |
| Profit before income tax | 1,370 | 21,191 | |
| Income taxes | (348) | (2,171) | |
| Net profit | 1,022 | 19,020 | |
| Group's share | 1,024 | 19,016 | |
| Minority share | (2) | 4 | |
| Basic net result per share (in Euro) | 0.01 | 0.11 | |
| Diluted net result per share (In Euro) | 0.01 | 0.11 |
Analysis of Reclassified Income Statement
| Period of 6 months ended 30 June | ||||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands of euro) | 2025 | of which non- recurring |
2025 Adjusted |
% | 2024 | of which non recurring |
2024 Adjusted |
% |
| Revenues from sales and services | 215,595 | 215,595 | 100.0% | 214,822 | 214,822 | 100.0% | ||
| Other revenues and income | 3,684 | 370 | 3,314 | 1.5% | 3,901 | 1,137 | 2,764 | 1.3% |
| Total revenue | 219,279 | 370 | 218,909 | 101.5% | 218,723 | 1,137 | 217,586 | 101.3% |
| Costs for purchase of raw materials and change in inventories |
(64,568) | (64,568) | -29.9% | (64,435) | (64,435) | -30.0% | ||
| Service provisions | (31,280) | (422) | (30,858) | -14.3% | (29,692) | (250) | (29,442) | -13.7% |
| Other operating expenses | (3,076) | (524) | (2,552) | -1.2% | (3,721) | (1,232) | (2,489) | -1.2% |
| Added value | 120,355 | (576) | 120,931 | 56.1% | 120,875 | (345) | 121,220 | 56.4% |
| Labour cost | (68,777) | (2,003) | (66,774) | -31.0% | (69,808) | (631) | (69,177) | -32.2% |
| EBITDA | 51,578 | (2,579) | 54,157 | 25.1% | 51,067 | (976) | 52,043 | 24.2% |
| Depreciation and amortisation Provisions and write-downs |
(22,336) (281) |
(7,993) | (14,343) (281) |
-6.7% -0.1% |
(21,874) (520) |
(8,034) | (13,840) (520) |
-6.4% -0.2% |
| EBIT | 28,961 | (10,572) | 39,533 | 18.3% | 28,673 | (9,010) | 37,683 | 17.5% |
| Financial income and expenses | (27,591) | (470) | (27,121) | -12.6% | (7,482) | (2,810) | (4,672) | -2.2% |
| Pre-tax result | 1,370 | (11,042) | 12,412 | 5.8% | 21,190 | (11,820) | 33,011 | 15.4% |
| Income taxes | (348) | 2,751 | (3,099) | -1.4% | (2,171) | 6,044 | (8,215) | -3.8% |
| Group and minorities' net profit | 1,022 | (8,291) | 9,313 | 4.3% | 19,020 | (5,776) | 24,796 | 11.5% |





Consolidated Balance Sheet
| (In thousands of Euro) | At 30 June 2025 | At 31 December 2024 |
|---|---|---|
| ASSETS | ||
| Non-current assets | ||
| Intangible assets | 438,594 | 472,940 |
| Right of use assets | 21,423 | 23,389 |
| Property, plant and equipment | 162,349 | 133,756 |
| Deferred tax assets | 839 | 859 |
| Non-current financial assets | 1,424 | 3,422 |
| Non- current derivative financial instruments | 264 | 1,877 |
| Total non current assets | 624,893 | 636,243 |
| Current assets | ||
| Inventories | 98,423 | 80,542 |
| Trade receivables | 61,636 | 55,368 |
| Contract assets | 1,625 | 1,561 |
| Income tax receivables | 15,866 | 10,768 |
| Other current assets and receivables | 15,463 | 11,893 |
| Current financial assets | 1 .846 | 30,985 |
| Current derivative financial instruments | 1,290 | |
| Cash and cash equivalents | 62,032 | 102,991 |
| Total current assets | 258,181 | 294,108 |
| TOTAL ASSETS | 883,074 | 930,351 |
| EQUITY AND LIABILITIES | ||
| Share capital | 1,892 | 1,892 |
| Reserves | 425,366 | 415,917 |
| Profit for the period | 1,024 | 33,370 |
| Group shareholders' equity | 428,282 | 451,179 |
| Non-controlling interests | 47 | 52 |
| Total equity | 428,329 | 451,231 |
| Non-current liabilities | ||
| Payables for the purchase of equity investments and earn-outs | 8,105 | 8,245 |
| Non-current borrowings | 203,472 | 246,021 |
| Non-current lease liabilities | 11,874 | 14,138 |
| Deferred tax liabilities | 29,928 | 29,937 |
| Employee benefit obligations | 3,025 | 2,924 |
| Provisions for risks and charges | 5,528 | 6,648 |
| Non-current derivative financial instruments | 399 | |
| Total non-current liabilities | 262,331 | 307,913 |
| Current liabilities | ||
| Payables for the purchase of equity investments and earn-outs | 7,474 | 19,346 |
| Current borrowings | 93,301 | 57,221 |
| Current lease liabilities | 7.276 | 8,034 |
| Current provisions for risks and charges | 725 | 500 |
| Current derivative financial instruments | 44 | 382 |
| Trade payables | 46,595 | 42,542 |
| Contract liabilities | 5,785 | 5,868 |
| Income tax payables | 6,259 | 10,159 |
| Other current liabilities | 24,955 | 27,155 |
| Total current liabilities | 192,414 | 171,207 |
| TOTAL EQUITY AND LIABILITIES | 883,074 | 930,351 |


IT-25917-9190.GVS1
Tel. +39 051 6176311 - Fax +39 051 6176200 - e-mail: [email protected] - www.gvs.com Cap. Soc. € 1.891.776,93 int. vers. - C.F. 03636630372 - P. Iva 00644831208 EMA DI GE8TIONE
CERTIFICATO

IATF 16049
Cert. N. 9136.0
R.E.A. 0305386/BO - Reg. Imprese 45539/BO - Mecc. BO 012048 UNI EN ISO 14001
Cert. N. 7838-E
A DI GESTIC
RTIFICATO UNI EN ISO 45001
Cert. N. 7838-l Mod 3065 rev 05


Consolidated Cash Flow Statement
| Period of 6 months ended 30 | |||
|---|---|---|---|
| (In thousands of Euro) | June | ||
| 2025 | 2024 | ||
| Profit before income tax | 1,370 | 21,191 | |
| - Adjustments: | |||
| Depreciation and amortization | 22,336 | 21,874 | |
| Capital loss / (gain) from disposal of assets | (64) | (રક) | |
| Net financial expenses | 27,591 | 7,482 | |
| Other non-monetary movements | 6,909 | 3,885 | |
| Cash flow from operating activities before changes in net working | 58,142 | 54,373 | |
| capital | |||
| Changes in inventory | (20,102) | (2,541) | |
| Changes in trade receivables | (8,122) | (7,362) | |
| Changes in trade payables | 2,893 | 6,118 | |
| Changes in other assets and liabilities | (7,247) | 2,063 | |
| Uses of employee benefit obligations and provisions for risks and | (4,486) | (1,344) | |
| charges | |||
| Income tax paid | (9,213) | (7,199) | |
| Net cash flow provided by / (used in) operating activities | 11,865 | 44,108 | |
| Investments in property, plant and equipment | (40,970) | (15,075) | |
| Investments in intangible assets | (3,605) | (4,141) | |
| Disposal of property, plant and equipment | 172 | 200 | |
| Investments in financial assets | (169) | (86,172) | |
| Disposal of financial assets | 28,271 | 10,000 | |
| Acquisition of company branch (net of cash acquired) | (19,128) | (19,000) | |
| Net cash flow provided by / (used in) investing activities | (35,429) | (114,189) | |
| Proceeds of borrowings | 20,041 | 208 | |
| Repayment of borrowings | (25,685) | (50,557) | |
| Repayment of lease liabilities | (4,451) | (4,593) | |
| Finance costs paid | (6,003) | (8,159) | |
| Finance income received | 758 | 1,270 | |
| Treasury shares | 97 | (154) | |
| Net cash flow provided by / (used in) financing activities | (15,243) | (61,984) | |
| Total cash flow provided / (used) in the year | (38,807) | (132,065) | |
| Cash and cash equivalents at the beginning of the period | 102,991 | 191,473 | |
| Total cash flow provided / (used) in the year | (38,807) | (132,065) | |
| Exchange differences from translation of cash and cash equivalents | (2,152) | (204) | |
| Cash and cash equivalents at the end of the period | 62,032 | 59,203 |

Cuini EN ISO 9001

IT-25917-9190.GVS1
GVS S.p.A.
Via Roma, 50 - 40069 Zola Predosa (Bologna) - Italy Tel. +39 051 6176311 - Fax +39 051 6176200 - e-mail: [email protected] - www.gvs.com EMA DI GE8TIONE
CERTIFICATO


Cap. Soc. € 1.891.776,93 int. vers. - C.F. 03636630372 - P. Iva 00644831208 R.E.A. 0305386/BO - Reg. Imprese 45539/BO - Mecc. BO 012048
UNI EN ISO 45001
Cert. N. 7838-l UNI EN ISO 14001
Cert. N. 7838-E
IATF 16049
Cert. N. 9136.0
Mod 3065 rev 05


Consolidated Net Financial Debt
| (In thousands of euro) | At 30 June 2025 | At 31 December 2024 | |
|---|---|---|---|
| (A) | Cash on hand | 62,032 | 102,991 |
| (B) | Cash equivalents | ||
| (C | Other current financial assets | 1,846 | 30,985 |
| (D) | Cash and cash equivalents (A)+(B)+(C) | 63,878 | 133,976 |
| (E | Current financial payables | 15,866 | 30,804 |
| (E | Current portion of non-current payables | 91,731 | 53,797 |
| (G) | Current financial debt (E) + (F) | 107,597 | 84,601 |
| (H) | Net current financial debt (G) - (D) | (43,719) | 49,375 |
| (1) | Non-current financial payables | 223,849 | 268,404 |
| (J) | Debt obligations | ||
| (K | Commercial and other non-current debt | 467 | 757 |
| (L) | Non-current financial debt (I) + (J) + (K) | 224,316 | 269,161 |
| (M) | Total net financial debt (H)-(L) | (268,035) | (219,786) |

Cuini EN ISO 9001

IT-25917-9190.GVS1
GVS S.p.A.



Via Roma, 50 - 40069 Zola Predosa (Bologna) - Italy Tel. +39 051 6176311 - Fax +39 051 6176200 - e-mail: [email protected] - www.gvs.com Cap. Soc. € 1.891.776,93 int. vers. - C.F. 03636630372 - P. Iva 00644831208 R.E.A. 0305386/BO - Reg. Imprese 45539/BO - Mecc. BO 012048
UNI EN ISO 14001
Cert. N. 7838-E
A DI GESTIC
RTIFICATO UNI EN ISO 45001
Cert. N. 7838-l